Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-28T16:07:21.929Z Has data issue: false hasContentIssue false

Selective Serotonin Reuptake Inhibitor Antidepressants

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 238 - 264
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Aurobindo Pharma Limited. (2019). Citalopram Package Insert. East Windsor, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: SSRI Protocol. Sacramento, California.Google Scholar
Gray, N. A., Milak, M. S., DeLorenzo, C., et al. (2013). Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry, 74, 26–31.Google Scholar
Kraus, C., Castren, E., Kasper, S., et al. (2017). Serotonin and neuroplasticity – links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev, 77, 317–326.Google Scholar
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.Google Scholar
Ferguson, J. M. (2001). SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry, 3, 22.Google ScholarPubMed

References

California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: SSRI Protocol. Sacramento, California.Google Scholar
Jubilant Cadista Pharmaceuticals Inc. (2019). Escitalopram Package Insert. Salisbury, Maryland.Google Scholar
Gray, N. A., Milak, M. S., DeLorenzo, C., et al. (2013). Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry, 74, 26–31.Google Scholar
Kraus, C., Castren, E., Kasper, S., et al. (2017). Serotonin and neuroplasticity – links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev, 77, 317–326.Google Scholar
Sánchez, C., Bøgesø, K. P., Ebert, B., et al. (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology, 174, 163–176.Google Scholar
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.Google Scholar
Ferguson, J. M. (2001). SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry, 3, 22.Google Scholar

References

Aurobindo Pharma Limited. (2019). Fluoxetine Package Insert and Label. East Windsor, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: SSRI Protocol. Sacramento, California.Google Scholar
Ni, Y., Miledi, R. (1997). Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci, 94, 2036–2040.CrossRefGoogle ScholarPubMed
Gray, N. A., Milak, M. S., DeLorenzo, C., et al. (2013). Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry, 74, 26–31.CrossRefGoogle ScholarPubMed
Kraus, C., Castren, E., Kasper, S., et al. (2017). Serotonin and neuroplasticity – links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev, 77, 317–326.CrossRefGoogle ScholarPubMed
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.Google Scholar
Ferguson, J. M. (2001). SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry, 3, 22.Google ScholarPubMed
Sager, J. E., Lutz, J. D., Foti, R. S., et al. (2014). Fluoxetine- and norfluoxetine-mediated complex drug–drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther, 95, 653–662.Google Scholar
Spina, E., de Leon, J. (2014). Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol, 10, 721–746.Google Scholar

References

Actavis Pharma, I. (2017). Fluvoxamine Extended Release Package Insert. Parsippany, New Jersey.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: SSRI Protocol. Sacramento, California.Google Scholar
Apotex Corp. (2020). Fluvoxamine Package Insert. Weston, Florida.Google Scholar
Gray, N. A., Milak, M. S., DeLorenzo, C., et al. (2013). Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry, 74, 26–31.CrossRefGoogle ScholarPubMed
Tsai, S. Y., Pokrass, M. J., Klauer, N. R., et al. (2014). Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders. Expert Opin Ther Targets, 18, 1461–1476.Google Scholar
Kraus, C., Castren, E., Kasper, S., et al. (2017). Serotonin and neuroplasticity – links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev, 77, 317–326.CrossRefGoogle ScholarPubMed
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.CrossRefGoogle ScholarPubMed
Ferguson, J. M. (2001). SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry, 3, 22.Google ScholarPubMed
Oliveira, P., Ribeiro, J., Donato, H., et al. (2017). Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry, 16, 17.CrossRefGoogle ScholarPubMed
Spina, E., de Leon, J. (2014). Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol, 10, 721–746.Google Scholar
Strauss, W. L., Layton, M. E., Dager, S. R. (1998). Brain elimination half-life of fluvoxamine measured by 19 F magnetic resonance spectroscopy. Am J Psychiatry, 155, 380–384.Google Scholar

References

California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: SSRI Protocol. Sacramento, California.Google Scholar
Rhodes Pharmaceuticals, L.P. (2019). Paroxetine Extended Release Package Insert. Coventry, Rhode Island.Google Scholar
Solco Healthcare, U.S. LLC. (2020). Paroxetine Package Insert. Somerset, New Jersey.Google Scholar
Gilmor, M. L., Owens, M. J., Nemeroff, C. B. (2002). Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry, 159, 1702–1710.Google Scholar
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.Google Scholar
Ferguson, J. M. (2001). SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry, 3, 22.Google Scholar
Spina, E., de Leon, J. (2014). Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol, 10, 721–746.CrossRefGoogle ScholarPubMed

References

Exelam Pharmaceuticals Inc. (2018). Sertraline Package Insert. Lawrenceville, Georgia.Google Scholar
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: SSRI Protocol. Sacramento, California.Google Scholar
Nemeroff, C. B., Owens, M. J. (2004). Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr, 9, 23–31.CrossRefGoogle ScholarPubMed
Gray, N. A., Milak, M. S., DeLorenzo, C., et al. (2013). Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry, 74, 26–31.Google Scholar
Kraus, C., Castren, E., Kasper, S., et al. (2017). Serotonin and neuroplasticity – links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev, 77, 317–326.CrossRefGoogle ScholarPubMed
Matsushima, Y., Terada, K., Kamei, C., et al. (2019). Sertraline inhibits nerve growth factor-induced neurite outgrowth in PC12 cells via a mechanism involving the sigma-1 receptor. Eur J Pharmacol, 853, 129–135.CrossRefGoogle Scholar
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.CrossRefGoogle ScholarPubMed
Ferguson, J. M. (2001). SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry, 3, 22.Google Scholar
Stahl, S. M. (2004). Selectivity of SSRIs: individualising patient care through rational treatment choices. Int J Psychiatry Clin Pract, 8, 3–10.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×